← Back to Search

Hormone Therapy

DMPA-SC for Birth Control

Phase 4
Recruiting
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial compares self-administered contraception to provider-administered contraception and will look at continuation rates, pregnancy, side effects, satisfaction & associations between patient characteristics & continuation. It will help increase access to self-administered contraception & patient contraceptive autonomy.

Who is the study for?
This trial is for patients who want to use Depot-Medroxyprogesterone Acetate (DMPA) as birth control after an abortion. Participants must be able to speak and read English, as the study involves self-administration teaching and follow-up surveys.Check my eligibility
What is being tested?
The study compares two methods of administering DMPA: self-injected subcutaneous (under the skin) and provider-administered intramuscular (into the muscle). It aims to see which method has higher continuation rates at 3 and 6 months post-abortion in a Chicago clinic.See study design
What are the potential side effects?
Possible side effects of DMPA include changes in menstrual periods, weight gain, headaches, stomach pain or discomfort, dizziness, breast tenderness, mood changes, or decreased sex drive. The extent of these side effects can vary among individuals.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
DMPA continuation rate

Trial Design

2Treatment groups
Active Control
Group I: DMPA-SCActive Control1 Intervention
self-administered subcutaneous depot medroxyprogesterone acetate 104 mg
Group II: DMPA-IMActive Control1 Intervention
provider-administered intramuscular depot medroxyprogesterone acetate 150 mg

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,579 Previous Clinical Trials
916,132 Total Patients Enrolled
Society of Family PlanningOTHER
98 Previous Clinical Trials
16,481 Total Patients Enrolled

Media Library

Depot-Medroxyprogestereone Acetate (Hormone Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05505435 — Phase 4
Birth Control Research Study Groups: DMPA-SC, DMPA-IM
Birth Control Clinical Trial 2023: Depot-Medroxyprogestereone Acetate Highlights & Side Effects. Trial Name: NCT05505435 — Phase 4
Depot-Medroxyprogestereone Acetate (Hormone Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05505435 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the Food and Drug Administration given their seal of approval to DMPA-IM?

"There is a considerable amount of research supporting DMPA-IM's safety, which was enough for it to be awarded the maximum score on our scale: 3. This decision was based off of its current status as an approved Phase 4 medication."

Answered by AI

Are there any unfilled positions available to participants in this experiment?

"Affirmative, the information on clinicaltrials.gov indicates that this study is actively seeking participants. It was inaugurated on August 1st 2022 and has recently been updated as of February 18th 2023. This trial requires 653 individuals across a single site to take part in it."

Answered by AI

How many participants have enrolled in the study thus far?

"Affirmative. Clinicaltrials.gov's records show that this study began recruiting on August 1st 2022, and was last updated on February 18th 2023. 653 participants need to be enrolled at one clinical site for the trial to continue as planned."

Answered by AI
~0 spots leftby Apr 2024